Abstract
High glucose uptake is a characteristic of most metastatic tumors and activation of Ras signaling in immortalized cells increases glycolytic flux into lactate, de novo nucleic acid synthesis and the tricarboxylic acid cycle, and increases NADH shuttling, oxygen consumption and uncoupling of ATP synthase from the proton gradient. Fructose-2,6- bisphosphate, C-Myc, HIF1α and AKT each have been found to be key regulators of glycolysis and to be controlled by Ras signaling, and there is abundant evidence for cross-talk between these regulators. The reprogramming of glycolytic and mitochondrial metabolism by Ras enables an integrated activation of energetic and anabolic pathways via the redox state of NADH that is required for the survival and growth of neoplastic cells in poorly vascularized tumors. Several small molecule antagonists specific for essential metabolic enzymes have been found to be selectively toxic to Ras-transformed cells as opposed to wild-type cells, indicating that this metabolic reprogramming and addiction may have utility for the development of anti-neoplastic agents.
Keywords: C-Myc, glycolysis, HIF1α, mitochondria, metabolism, phosphofructokinase, Ras
Current Pharmaceutical Biotechnology
Title:Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Volume: 14 Issue: 3
Author(s): J. Chesney and S. Telang
Affiliation:
Keywords: C-Myc, glycolysis, HIF1α, mitochondria, metabolism, phosphofructokinase, Ras
Abstract: High glucose uptake is a characteristic of most metastatic tumors and activation of Ras signaling in immortalized cells increases glycolytic flux into lactate, de novo nucleic acid synthesis and the tricarboxylic acid cycle, and increases NADH shuttling, oxygen consumption and uncoupling of ATP synthase from the proton gradient. Fructose-2,6- bisphosphate, C-Myc, HIF1α and AKT each have been found to be key regulators of glycolysis and to be controlled by Ras signaling, and there is abundant evidence for cross-talk between these regulators. The reprogramming of glycolytic and mitochondrial metabolism by Ras enables an integrated activation of energetic and anabolic pathways via the redox state of NADH that is required for the survival and growth of neoplastic cells in poorly vascularized tumors. Several small molecule antagonists specific for essential metabolic enzymes have been found to be selectively toxic to Ras-transformed cells as opposed to wild-type cells, indicating that this metabolic reprogramming and addiction may have utility for the development of anti-neoplastic agents.
Export Options
About this article
Cite this article as:
Chesney J. and Telang S., Regulation of Glycolytic and Mitochondrial Metabolism by Ras, Current Pharmaceutical Biotechnology 2013; 14 (3) . https://dx.doi.org/10.2174/1389201011314030002
DOI https://dx.doi.org/10.2174/1389201011314030002 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Hedgehog Signaling and Urological Cancers
Current Drug Targets Meet our Editorial Board Member
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell Death: Tipping the Balance of Autoimmunity and Tissue Repair
Current Pharmaceutical Design Molecular Pathways and Related Target Therapies in Liver Carcinoma
Current Pharmaceutical Design Biological Activity of Some Volatile Diterpenoids
Current Bioactive Compounds Tumor Systems Need to be Rendered Usable for a New Action-Theoretical Abstraction: The Starting Point for Novel Therapeutic Options
Current Cancer Therapy Reviews Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Neutrophil Elastase as a Target in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Applications of Diphenylamine and Its Derivative as Potent Bioactive Compound: A Review
Current Bioactive Compounds Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes
CNS & Neurological Disorders - Drug Targets Innate and Adaptive Immune Responses in Allergic Contact Dermatitis and Autoimmune Skin Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Plant and Animal Steroids a New Hope to Search for Antiviral Agents
Current Medicinal Chemistry Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry